TY - JOUR T1 - Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer JF - Anticancer Research JO - Anticancer Res SP - 2475 LP - 2482 DO - 10.21873/anticanres.13367 VL - 39 IS - 5 AU - MARIA V. CHRISTENSEN AU - CLAUS HØGDALL AU - STEFFEN G. JENSEN AU - NOOR LOKMAN AU - CARMELA RICCIARDELLI AU - IB J. CHRISTENSEN AU - PERNILLE CHRISTIANSEN AU - JULIE BRASK AU - MONA A. KARLSEN AU - THERESE K. NISSEN AU - KIRSTEN M. JOCHUMSEN AU - ESTRID HØGDALL Y1 - 2019/05/01 UR - http://ar.iiarjournals.org/content/39/5/2475.abstract N2 - Background/Aim: Ovarian cancer (OC) is the 5th most common cancer among European women. Approximately 70-80% of OC is diagnosed at advanced stage resulting in an elevated mortality rate. The aim of this study was to examine whether Annexin A2 and S100A10 expression can be used as prognostic markers for epithelial ovarian cancer (EOC). Materials and Methods: Expression of Annexin A2 and S100A10 was evaluated in EOC tissue samples (n=303) by immunohistochemistry. The staining of the membrane, cytoplasmic and stroma was assessed according to intensity. Results: The expression of both markers correlated to histological subtype, histological grading, International Federation of Gynecology and Obstetrics (FIGO) stage, and macro-radical surgery. Univariate Cox regression analysis showed that Annexin A2 and S100A10 in stromal tissue correlated with shorter overall survival (OS). Multivariate Cox regression analysis demonstrated no independent prognostic significance of stromal Annexin A2 expression. Conclusion: High expression of Annexin A2 and S100A10 in stromal tissue from EOC patients was associated with reduced OS; however, no independent prognostic value was found for any of the markers. ER -